@article{d3598c833d7440809595d3f18490304e,
title = "Relationship between regional gray matter volumes and dopamine D2 receptor and transporter in living human brains",
abstract = "Although striatal dopamine neurotransmission is believed to be functionally linked to the formation of the corticostriatal network, there has been little evidence for this regulatory process in the human brain and its disruptions in neuropsychiatric disorders. Here, we aimed to investigate associations of striatal dopamine transporter (DAT) and D2 receptor availabilities with gray matter (GM) volumes in healthy humans. Positron emission tomography images of D2 receptor (n = 34) and DAT (n = 17) captured with the specific radioligands [11C]raclopride and [18F]FE-PE2I, respectively, were acquired along with T1-weighted magnetic resonance imaging data in our previous studies, and were re-analyzed in this work. We quantified the binding potentials (BPND) of these radioligands in the limbic, executive, and sensorimotor functional subregions of the striatum. Correlations between the radioligand BPND and regional GM volume were then examined by voxel-based morphometry. In line with the functional and anatomical connectivity, [11C]raclopride BPND in the limbic striatum was positively correlated with volumes of the uncal/parahippocampal gyrus and adjacent temporal areas. Similarly, we found positive correlations between the BPND of this radioligand in the executive striatum and volumes of the prefrontal cortices and their adjacent areas as well as between the BPND in the sensorimotor striatum and volumes of the somatosensory and supplementary motor areas. By contrast, no significant correlation was found between [18F]FE-PE2I BPND and regional GM volumes. Our results suggest unique structural and functional corticostriatal associations involving D2 receptor in healthy humans, which might be partially independent of the nigrostriatal pathway reflected by striatal DAT.",
keywords = "D receptor, MRI, PET, dopamine transporter, gray matter, striatum",
author = "Shin Kurose and Manabu Kubota and Keisuke Takahata and Yasuharu Yamamoto and Hironobu Fujiwara and Yasuyuki Kimura and Hiroshi Ito and Hiroyoshi Takeuchi and Masaru Mimura and Tetsuya Suhara and Makoto Higuchi",
note = "Funding Information: Dr. Kurose has received research grants from JSPS. Dr. Kubota has received research grants from JSPS, SENSHIN Medical Research Foundation, and Medical Institute of Developmental Disabilities Research, Showa University. Dr. Takahata has received research grants from JSPS and the General Insurance Association of Japan. Dr. Yamamoto has no competing interests to disclose. Dr. Fujiwara has received research grants from JSPS. Dr. Kimura has received research grants from JSPS, Japan Agency for Medical Research and Development (AMED), and National Center for Geriatrics and Gerontology. Dr. Ito has received research grants from JSPS. Dr. Takeuchi has received research grants from JSPS, Japan Agency for Medical Research and Development (AMED), SENSHIN Medical Research Foundation, and Novartis Pharma; fellowship grants from Astellas Foundation for Research on Metabolic Disorders, the Canadian Institutes of Health Research (CIHR), Centre for Addiction and Mental Health (CAMH) Foundation, and the Japanese Society of Clinical Neuropsychopharmacology (JSCNP); speaker's fees from Kyowa, Janssen, Meiji Seika Pharma, Mochida, Otsuka, Sumitomo Dainippon Pharma, and Yoshitomiyakuhin; and manuscript fees from Sumitomo Dainippon Pharma. Dr. Mimura has received research grants from JSPS, AMED and Japan Ministry of Health, Labour and Welfare. Dr. Suhara has received research grants from AMED and Japan Ministry of Health, Labour and Welfare. Dr. Higuchi has received research grants from JSPS, AMED and Japan Ministry of Health, Labour and Welfare. Funding Information: We thank Kazuko Suzuki and Izumi Kaneko for their assistance as clinical coordinators, Hiromi Sano for her support with MRI scans, and the staff of the Department of Radiopharmaceutics Development for the radioligand synthesis. This work was supported in part by a Grant‐in‐Aid for Young Scientist (19K17101 to MK) from the Japan Society for the Promotion of Science (JSPS), and by the programs for Brain/MINDS‐beyond (19dm0307105 to MH) and Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS; 20dm0207072 to MH) from the Japan Agency for Medical Research and Development. These agencies had no further role in the study design, collection, analysis, or interpretation of the data, the writing of the report, or in the decision to submit the paper for publication. Publisher Copyright: {\textcopyright} 2021 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.",
year = "2021",
month = aug,
day = "15",
doi = "10.1002/hbm.25538",
language = "English",
volume = "42",
pages = "4048--4058",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "12",
}